ES2762501T3 - Composición de anticuerpo y sistema amortiguador para la misma - Google Patents

Composición de anticuerpo y sistema amortiguador para la misma Download PDF

Info

Publication number
ES2762501T3
ES2762501T3 ES14730479T ES14730479T ES2762501T3 ES 2762501 T3 ES2762501 T3 ES 2762501T3 ES 14730479 T ES14730479 T ES 14730479T ES 14730479 T ES14730479 T ES 14730479T ES 2762501 T3 ES2762501 T3 ES 2762501T3
Authority
ES
Spain
Prior art keywords
buffer
antibody
acid
pka
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14730479T
Other languages
English (en)
Spanish (es)
Other versions
ES2762501T8 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innova Biosciences Ltd
Original Assignee
Innova Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innova Biosciences Ltd filed Critical Innova Biosciences Ltd
Application granted granted Critical
Publication of ES2762501T3 publication Critical patent/ES2762501T3/es
Publication of ES2762501T8 publication Critical patent/ES2762501T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
ES14730479T 2013-05-31 2014-05-30 Composición de anticuerpo y sistema amortiguador para la misma Active ES2762501T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1309759.7A GB2516808A (en) 2013-05-31 2013-05-31 Antibody composition and buffer system therefor
PCT/EP2014/061281 WO2014191560A1 (en) 2013-05-31 2014-05-30 Antibody composition and buffer system therefor

Publications (2)

Publication Number Publication Date
ES2762501T3 true ES2762501T3 (es) 2020-05-25
ES2762501T8 ES2762501T8 (es) 2020-06-18

Family

ID=48805557

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14730479T Active ES2762501T3 (es) 2013-05-31 2014-05-30 Composición de anticuerpo y sistema amortiguador para la misma

Country Status (9)

Country Link
US (1) US11046753B2 (enExample)
EP (1) EP3003385B1 (enExample)
JP (2) JP2016530216A (enExample)
CN (1) CN105592860B (enExample)
AU (1) AU2014273034B2 (enExample)
DK (1) DK3003385T3 (enExample)
ES (1) ES2762501T3 (enExample)
GB (2) GB2516808A (enExample)
WO (1) WO2014191560A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170189548A1 (en) * 2015-11-25 2017-07-06 Immunogen, Inc. Pharmaceutical formulations and methods of use thereof
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN111896752A (zh) * 2020-08-11 2020-11-06 上海捷门生物技术有限公司 一种适用于多种poct类仪器的c-反应蛋白试剂盒
CN113671188A (zh) * 2021-08-10 2021-11-19 江南大学 一种检测贝类食品中河豚毒素的时间分辨免疫定量试纸条
EP4218562A1 (en) 2022-01-28 2023-08-02 Charité - Universitätsmedizin Berlin Real-time breath antigen detection system and method thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0516873A1 (en) 1991-06-06 1992-12-09 THE STATE of ISRAEL Atomic Energy Commission Soreq Nuclear Research Center A method and kit for protein labelling with 99 mTC
ATE260674T1 (de) * 1998-08-17 2004-03-15 Pfizer Prod Inc Stabilisierte proteinzusammensetzung
EP1871803B1 (en) * 2005-04-18 2013-02-20 Yeda Research And Development Company Limited Stabilized anti-hepatitis b (hbv) antibody formulations
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CN101330931B (zh) * 2005-12-12 2012-09-05 创新生物科学有限公司 制备缀合物
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
CA2790018C (en) * 2006-12-21 2015-02-03 Amgen Inc. Formulations
CN102089662B (zh) 2008-07-16 2015-05-27 雷迪奥米特医学公司 高容量固相
JP2011241206A (ja) 2010-04-23 2011-12-01 Arkray Inc 標識抗体の安定化方法
EP2583973B1 (en) 2010-06-21 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
US8877892B2 (en) * 2011-03-15 2014-11-04 Innova Biosciences Limited Conjugation reactions
EP2686334B2 (en) 2011-03-16 2020-07-01 F.Hoffmann-La Roche Ag Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase
KR20120128440A (ko) 2011-05-17 2012-11-27 삼성전자주식회사 표적 물질 검출용 키트 및 이를 이용한 표적 물질 검출 방법

Also Published As

Publication number Publication date
GB201309759D0 (en) 2013-07-17
GB201522774D0 (en) 2016-02-03
US11046753B2 (en) 2021-06-29
WO2014191560A1 (en) 2014-12-04
AU2014273034B2 (en) 2019-11-21
JP2016530216A (ja) 2016-09-29
ES2762501T8 (es) 2020-06-18
JP2020007343A (ja) 2020-01-16
US20160122416A1 (en) 2016-05-05
AU2014273034A1 (en) 2016-01-28
CN105592860B (zh) 2021-02-02
GB2516808A (en) 2015-02-11
EP3003385B1 (en) 2019-09-18
GB2530217A (en) 2016-03-16
EP3003385A1 (en) 2016-04-13
DK3003385T3 (da) 2020-01-06
CN105592860A (zh) 2016-05-18

Similar Documents

Publication Publication Date Title
ES2762501T3 (es) Composición de anticuerpo y sistema amortiguador para la misma
CN110650969B (zh) 蛋白质稳定剂及蛋白质稳定试剂
ES2627482T3 (es) Procedimiento para la detección de una proteína de unión multiespecífica
CN107624115A (zh) 肉毒神经毒素特异性捕获剂、组合物、使用方法和制造方法
ES2800164T3 (es) Medios y métodos para la funcionalización específica de sitio de polipéptidos
US9718768B2 (en) System for purifying, producing and storing biomolecules
Teixeira-Clerc et al. How do short neurotoxins bind to a muscular-type nicotinic acetylcholine receptor?
US12493045B2 (en) Multi-target crosslinkers and uses thereof
JP2022537337A (ja) 金属錯体試薬を介するＨｉｓタグ付タンパク質などの標的分子への標識および／または担体の部位特異的、速度論的に不活性なコンジュゲーション
Marquez et al. Enhancing peptide ligand binding to vascular endothelial growth factor by covalent bond formation
ES2658420T3 (es) Método de síntesis de ADC utilizando resinas de afinidad
Cai et al. Peptoid ligands that bind selectively to phosphoproteins
Mohsenin et al. PenTag, a Versatile Platform for Synthesizing Protein‐Polymer Biohybrid Materials
ES2906117T3 (es) Conjugados de androstenodiona quimioluminiscente
Schumann et al. Identification of low abundance cyclophilins in human plasma
Geoghegan Modification of amino groups
ES2611827T3 (es) Ensayo para bencilpiperazinas y metabolitos
Wuenschell et al. Chiral copper—chelate complexes alter selectivities in metal affinity protein partitioning
CN101228442B (zh) 生物样品中肽的稳定方法
Ylikotila et al. Improved surface stability and biotin binding properties of streptavidin coating on polystyrene
Nath et al. Antibody labeling with fluorescent dyes using magnetic protein A and protein G beads
JP6867289B2 (ja) 合成ビエピトープ化合物
Arai et al. Fluorescent “Turn-on” system utilizing a quencher-conjugated peptide for specific protein labeling of living cells
Vetter et al. Affinity purification of the avidin protein family, based on crystal structures of avidin-HABA complexes
ES2888930T3 (es) Estabilización de la glutamato deshidrogenasa en solución acuosa